Filing Flows

Filing Flows › 8-K events › CorMedix

CorMedix: entry into a material definitive agreement

Form 8-K filed Nov 9, 2026 · items 1.01, 2.03, 3.02, 7.01

Mergers and acquisitionsCorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care

What the filing says

On November 8, 2026, CorMedix Inc., a Delaware corporation (the “Company,” “CorMedix,” “we,” “our” and “us”), and Heron Therapeutics, Inc., a Delaware corporation (the “Seller” or “Heron”), entered into an Asset Purchase Agreement (the “Purchase Agreement”), pursuant to which the Seller has agreed to sell substantially

Read the filing on SEC EDGAR →

What usually followsAcross 23,535 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 2.03: 0.0% next session across 13,276. Item 3.02: +0.2% next session across 2,752. Every item ranked →

What this kind of filing means

Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.

Item 2.03 — Creation of a direct financial obligation. New debt or a guarantee: the amount, the rate and the maturity set the cost of capital and the repayment wall ahead.

CorMedix at a glance

Latest quarterQ2 2026
Revenue$101.9M
Revenue Y/Y+156%
Operating margin42.1%
IndustryPharmaceutical Preparations

CorMedix, Q2 2026: revenue $102M (+156% year over year), operating margin 42.1%. The chart follows the revenue to costs, profit and cash.

CorMedix: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent mergers and acquisitions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.